Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study
Open Access
- 25 December 2022
- Vol. 15 (1), 65
- https://doi.org/10.3390/v15010065
Abstract
As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during the TüSeRe: exact study (Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung). Employees of health and research institutions were invited to participate. Study participants were asked to fill out an online questionnaire and report their SE after each dose of SARS-CoV-2 vaccination. A total of 1046 participants (mean age: 44 ± 12.9 years; female, n = 815 (78%); male, n = 231 (22%)) were included in the analysis. Local and systemic SE were more frequent after receiving the vector-based vaccine ChAdOx1 nCoV-19 in the first vaccination. However, local and systemic SE were more common after receiving mRNA vaccines (BNT162b2, mRNA-1273) in the second vaccination. Compared to the BNT162b2 vaccine, more SE have been observed after receiving the mRNA-1273 vaccine in the booster vaccination. In multivariate analysis, local and systemic side effects were associated with vaccine type, age and gender. Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE differ significantly between mRNA and vector-based vaccines.Keywords
Funding Information
- German Research Foundation (BA5158/4)
- Herzstiftung (BA5158/4)
- state of Baden-Württemberg for coagulation research and Blood donation service of the German Red Cross (FKZ 3-4332.62-NMI-67, FKZ 3-4332.62-NMI-68)
This publication has 33 references indexed in Scilit:
- Maintaining Safety with SARS-CoV-2 VaccinesThe New England Journal of Medicine, 2021
- COVID-19 vaccines: The status and perspectives in delivery points of viewAdvanced Drug Delivery Reviews, 2020
- SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics DevelopmentFrontiers in Cellular and Infection Microbiology, 2020
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- The origin and underlying driving forces of the SARS-CoV-2 outbreakJournal of Biomedical Science, 2020
- Evidence based management guideline for the COVID-19 pandemic - Review articleInternational Journal of Surgery, 2020
- First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020Eurosurveillance, 2020
- Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained ImmunityCell, 2018
- Adenovirus sensing by the immune systemCurrent Opinion in Virology, 2016
- Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and PreventionSeminars in Respiratory and Critical Care Medicine, 2016